Pfizer Settles FCPA Charges; Settlement Lessened by Company’s Compliance Steps

Drug Industry Daily
A A
Pfizer will pay $60 million to resolve Foreign Corrupt Practices Act charges, but its proactive corporate compliance program allowed it to avoid even harsher penalties — including imposition of an outside corporate monitor.

To View This Article:

Login

Subscribe To Drug Industry Daily